Inhibitors of the renin-angiotensin system and angiotensin II receptor blockers have been used to decrease hyperflow, intraglomerular hypertension, proteinuria, and systemic blood pressure, consequently delaying GFR decreases.18-22 Drugs in these classes are prescribed in the early stages of CKD, particularly to individuals with diabetes. The gene discussed is REN; the disease is chronic kidney disease.